Myocardial protection at a crossroads: the need for translation into clinical therapy

Roberto Bolli1, Lance Becker, Garrett Gross

  • 1Heart Research Program, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health & Human Services, Bethesda, Md 20892, USA.

Circulation Research
|July 24, 2004
PubMed

Insights

Translating cardioprotective therapies from animal studies to human clinical practice has failed. A new focus on rigorous preclinical testing and multicenter trials is needed for effective heart protection strategies.

Area of Science:

  • Cardiovascular Research
  • Translational Medicine
  • Pharmacology

Background:

  • Hundreds of experimental cardioprotective interventions for ischemic myocardium have not translated to clinical practice over 30 years.
  • Existing basic research approaches are inefficient, leading to inconclusive results from single-center studies.
  • Cardioprotection for acute myocardial infarction, cardiac surgery, and arrest is at a critical juncture.

Purpose of the Study:

  • To identify reasons for the failure in translating cardioprotective therapies from animal models to human clinical practice.
  • To recommend new approaches for effective translation of basic science findings into clinical use.
  • To establish a new paradigm for cardioprotective research and development.

Main Methods:

  • Convened a National Heart, Lung, and Blood Institute working group to discuss translation challenges.
  • Reviewed existing basic research and preclinical testing methodologies.
  • Proposed a new translational research framework emphasizing efficacy and clinical outcomes.

Main Results:

  • Current basic research methods for identifying cardioprotective therapies are inefficient and counterproductive.
  • Significant investment in single-center studies has yielded inconclusive results.
  • A new paradigm focusing on rigorous preclinical testing is essential for successful translation.

Conclusions:

  • A new focus on translational research with clinically relevant outcomes is urgently needed.
  • Establishment of a national preclinical research consortium for rigorous testing is recommended.
  • NIH intervention is recommended, including a preclinical consortium and Phase III trials of adenosine.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...